Urgent.News

What's breaking now, across thousands of outlets.

More in Finance & Markets

Geron: 3 Key Takeaways for Long-Term Investors

Operating expenses fell 9% year to date, and $339 million in cash leaves Geron room to pursue hematology deals.

  • Geron's Q3 2026 revenue grew 27% year-over-year to $60.1 million
  • CEO highlighted community clinics' role in driving prescriptions
  • Geron will launch RYTELO in Germany by year-end using hybrid pricing model

More from Thursday 5 November →